Flubendazole as a macrofilaricide: History and background.
Albendazole
/ therapeutic use
Animals
Diethylcarbamazine
/ therapeutic use
Elephantiasis, Filarial
/ drug therapy
Filaricides
/ therapeutic use
Gastrointestinal Diseases
/ drug therapy
Humans
Ivermectin
/ therapeutic use
Mebendazole
/ analogs & derivatives
Microfilariae
/ drug effects
Onchocerca volvulus
/ drug effects
Onchocerciasis
/ drug therapy
Wuchereria bancrofti
/ drug effects
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
15
2
2019
Statut:
epublish
Résumé
Benzimidazole anthelmintics have long been employed for the control of soil-transmitted helminth infections. Flubendazole (FBZ) was approved in 1980 for the treatment of gastrointestinal nematode infections in both veterinary and human medicine. It has also long been known that parenteral administration of FBZ can lead to high macrofilaricidal efficacy in a variety of preclinical models and in humans. As part of an effort to stimulate the discovery and development of new macrofilaricides, particularly for onchocerciasis, research has recently been devoted to the development of new formulations that would afford high oral bioavailability of FBZ, paving the way for potential clinical development of this repurposed drug for the treatment of human filariases. This review summarizes the background information that led to this program and summarizes some of the lessons learned from it.
Identifiants
pubmed: 30650160
doi: 10.1371/journal.pntd.0006436
pii: PNTD-D-18-00109
pmc: PMC6334891
doi:
Substances chimiques
Filaricides
0
Ivermectin
70288-86-7
Mebendazole
81G6I5V05I
Albendazole
F4216019LN
flubendazole
R8M46911LR
Diethylcarbamazine
V867Q8X3ZD
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0006436Déclaration de conflit d'intérêts
I have read the journal’s policy, and the authors of this manuscript have the following competing interests: SAS is an employee of Johnson & Johnson. Both TGG and CDM have served as consultants for Johnson & Johnson for some aspects of the work described in this submission.
Références
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0007026
pubmed: 30650076
J Infect Dis. 2015 Sep 1;212(5):684-93
pubmed: 25657255
Int J Parasitol Drugs Drug Resist. 2015 Jul 07;5(3):135-40
pubmed: 26288741
Sci Rep. 2017 Mar 16;7(1):210
pubmed: 28303006
Clin Infect Dis. 2016 Feb 1;62(3):334-341
pubmed: 26486704
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006787
pubmed: 30650084
PLoS Negl Trop Dis. 2016 May 04;10(5):e0004698
pubmed: 27145083
PLoS Negl Trop Dis. 2015 Feb 20;9(2):e0003534
pubmed: 25700363
Reprod Toxicol. 2014 Nov;49:33-42
pubmed: 24994687
Reprod Toxicol. 2013 Apr;36:78-87
pubmed: 23287076
Lancet. 1997 Jul 5;350(9070):18-22
pubmed: 9217715
J Vet Pharmacol Ther. 2017 Oct;40(5):493-499
pubmed: 28092103
Lancet. 1983 Jan 22;1(8317):139-43
pubmed: 6130195
PLoS Negl Trop Dis. 2014 May 29;8(5):e2838
pubmed: 24874646
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005163
pubmed: 28056015
Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):288-296
pubmed: 27733308
Parasitology. 2014 Jan;141(1):119-27
pubmed: 23866958
Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):272-286
pubmed: 27693536
Curr Opin Infect Dis. 2012 Dec;25(6):709-17
pubmed: 23041774
Infect Dis Poverty. 2016 May 24;5(1):54
pubmed: 27388873
Am J Trop Med Hyg. 2018 Jan;98(1):21-26
pubmed: 29141764
PLoS Negl Trop Dis. 2019 Jan 16;13(1):e0006320
pubmed: 30650105
PLoS Negl Trop Dis. 2015 May 21;9(5):e0003703
pubmed: 25996946
Expert Rev Anti Infect Ther. 2011 Aug;9(8):681-95
pubmed: 21819332
Filaria J. 2003 Oct 24;2 Suppl 1:S10
pubmed: 14975067
Mutagenesis. 2016 May;31(3):309-21
pubmed: 26443851
J Pharm Sci. 2016 Sep;105(9):2782-2793
pubmed: 27113473
Expert Rev Anti Infect Ther. 2011 May;9(5):497-501
pubmed: 21609260
Lancet. 2010 Oct 2;376(9747):1175-85
pubmed: 20739055